Clinical trial
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV…
NCT00339040 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00339040 |
|---|---|
| Title | Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children |
| Official title | Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections, Sexually Transmitted Diseases |
| Intervention type | Biological, Other |
| Interventions | Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV), Placebo/QHPV |
| Enrollment | 130 |
| Start date | Oct 1, 2006 |
| Primary completion | Aug 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Jun 20, 2006 |
| Last update posted | Nov 5, 2021 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: